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The success of liver transplantation
has resulted in a demand for grafts
that exceeds the number of avail-
able organs. Organ donation is there-
fore crucial. This rate of donation
depends on numerous factors, includ-
ing intensive care capacity, funding
for organ donation programmes and
public awareness. In addition, legisla-
tion regarding potential organ donors
(opting out or opting in to donation)
can inﬂuence the number of avail-
able organs in a country, although
the association between a legislative
framework and the level of accep-
tance rates or absolute number of
donors remains unclear1. A well orga-
nized donation infrastructure along
with local commitment for maximiz-
ing donation appears to be much
more important than any other strate-
gies, but this is a difﬁcult goal to
achieve. Other measures have there-
fore been proposed to increase the
pool of available organs. Among those
approaches are donation after cardiac
death (DCD), the use of fatty or older
livers, or the acceptance of donors pre-
senting with a history of cancer. In this
issue of BJS, three articles attempt
to address the impact of donor age
on DCD liver grafts2, the baseline
cellular energy status of DCD liver
grafts3 and the risk of cancer trans-




Programmes using liver grafts
obtained from DCD donors are active
in the USA and in six European
countries (Spain, UK, Belgium, The
Netherlands, Switzerland and Aus-
tria). Donors younger than 50 years
of age, total donor warm ischaemia
time of less than 30 min, and cold
ischaemia times below 6 h have been
identiﬁed as important targets to
minimize post-transplant intrahepatic
cholangiopathy5–10. These widely
accepted risk factors are challenged
by the study of Detry and colleagues2.
The authors suggest that donor age
per se is no longer a contraindication
to DCD liver transplantation. They
found that graft survival of DCD
livers was not affected by higher
donor age, up to 3 years after trans-
plantation, when comparing donors
older or younger than 70 years. This
observation was made, however, in
the setting of limited normothermic
(less than 20 min) and cold (3·9 h)
ischaemic periods. Such attractive
ischaemia times could be achieved
only by the implementation of a
so-called ‘comfort therapy’ with the
use of the volatile anaesthetic agent
sevoﬂurane during the withdrawal
phase of life support. Sevoﬂurane
causes rapid anoxia leading, in this
series, to a shorter withdrawal phase
(median time 11 min). This agent may
also confer organ protection through
a nitric oxide pathway11. In addition,
circulatory arrest was deﬁned by an
arterial pressure below 40 mmHg,
which is an unusual practice in most
areas, and the subsequent ‘no touch’
period was limited to 5 min.
Such an approach would not be pos-
sible in many other countries because
of strict ethical regulations. For
example, in Switzerland the median
total warm ischaemia time in donors
is 40 min owing to the requirement
for certifying brain death after car-
diac arrest12. As a result, oxygenated
cold machine perfusion is used to res-
cue these marginal grafts12. Whether
donor age inﬂuences outcome in these
types of DCD liver, and whether pro-
tective strategies are effective regard-
less of age, has yet to be demonstrated.
Optimizing strategies for liver
grafts
Liver grafts exposed to cold or warm
ischaemia undergo multiple biochem-
ical and morphological changes, with
a switch from aerobic to anaerobic
metabolism. DCD organs, in par-
ticular, have to tolerate continuous
cellular energy consumption during
donor downtime, owing to a lack of
tissue oxygen. In donors with long
intervals of warm ischaemia, new opti-
mizing strategies are therefore needed
to avoid irreversible injury to the
bile ducts. The article by Perera and
co-workers3 shows key differences in
cellular metabolism between human
DCD and donation after brainstem
death (DBD) liver grafts measured
by microdialysis. The authors found
cumulated interstitial lactate and glyc-
erol levels in ischaemic livers, con-
sistent with previous data in animal
models13.
Although traditional static cold
storage is unlikely to prevent tissue
acidosis, machine perfusion appears to
be an attractive means of changing
biochemical pathways, either before
or after procurement, by introduc-
ing oxygen to hypoxic tissue. Three
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approaches to machine liver perfu-
sion have been reported, differing
in perfusate temperature (normo-
thermic, subnormothermic and hypo-
thermic) and the degree of oxygena-
tion. Normothermic machine liver
perfusion simulates in vivo conditions,
and needs dual perfusion through the
portal vein and the hepatic artery
at physiological ﬂow and tempera-
ture with oxygenated diluted blood
and nutritional compounds as per-
fusate. In contrast, both subnormo-
thermic (20–25◦C) and hypothermic
(2–10◦C) machine liver perfusion rely
on the dissolved oxygen in a blood-
free perfusate. Human data on ex situ
normothermic or subnormothermic
oxygenated liver perfusion and sub-
sequent transplantation are awaited.
Preliminary data on discarded human
livers suggest the feasibility of both
approaches14,15, and the ﬁrst clinical
results after transplantation of cold
perfused DCD12 and DBD16 livers
suggest beneﬁt.
Expanding the organ donor
pool
Transmission of malignant cells by
transplantation is a rare, but highly
feared, risk in the immunosuppressed
patient. Guidelines have been devel-
oped to minimize the risk of cancer
transmission. The actual risk of can-
cer transmission by donors against the
mortality of patients waiting for a graft
in the UK is therefore welcomed4.
Sixty-one (0·4 per cent) of 17 369
donors were identiﬁed retrospectively
to carry a high risk of transmission
of cancer, according to current
guidelines4. During 10 years of follow-
up, however, no cancer transmis-
sion was recorded in any recipi-
ent receiving an organ from those
donors. Instead, the additional sur-
vival beneﬁt of transplanting organs
from donors with an unacceptable risk
of cancer transmission accumulated
to 944 life-years gained. This ﬁnd-
ing may justify careful expansion of
the donor pool by modifying present
guidelines. For example, based on
this, patients with curative resected
melanoma with a tumour thickness
of less than 1 mm, or women with
curatively resected stage 1 breast
cancer, could be considered for organ
donation, after a minimum cancer-
free period of 5 years. As a means
of extending the donor pool for solid
organ transplantation, conﬁrmation of
these results should result in revised
guidelines.
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